Considering Cost-Effectiveness of Cardiovascular and Kidney Complications of Type 2 Diabetes With Widespread Use of SGLT2i and GLP-1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Diabetologia 2023 Apr 01;66(4)642-656, JI Morton, C Marquina, JE Shaw, D Liew, KR Polkinghorne, Z Ademi, DJ MaglianoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.